Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04097704 · ClinicalTrials.gov registry record
Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort
A clinical trial, sponsored by Celgene.
- Completed
- Registry status
- 28
- Enrollment target
NCT04097704: Completed study, sponsored by Celgene.
NCT04097704 is a clinical trial that has completed, run by Celgene. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04097704 has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
This is a multi-center observational follow-up study to collect saliva samples that allow pharmacogenetic analysis of the subjects that participated in the CC-90007-CP-003 study. Approximately 28 subjects with moderate and severe hepatic impairment and healthy control subjects with normal hepatic function will be enrolled.
Primary Outcome
DNA Quality
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-09-04 |
| Est. Completion | 2019-11-01 |
What the finished NCT04097704 record still lists
NCT04097704 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04097704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04097704 about?
NCT04097704 is a clinical study titled "Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort". This is a multi-center observational follow-up study to collect saliva samples that allow pharmacogenetic analysis of the subjects that participated in the CC-90007-CP-003 study. Approximately 28 subjects with moderate and severe hepatic impairment and healthy control subjects with normal hepatic f...
What is the current status of trial NCT04097704?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2019-09-04. Estimated completion is 2019-11-01.
Who is sponsoring clinical trial NCT04097704?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI